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Recent evidence has demonstrated the presence of bacterial biofilms on the mucosa of 
patients with Chronic Rhinosinusitis (CRS), suggesting their role in the pathogenesis of the 
condition. This thesis contains two separate studies. The studies investigated novel topical 
therapies by using previously established in vitro and in vivo biofilm growth and detection 
methods. In the first study, several different proposed anti-biofilm agents were evaluated in 
a sheep biofilm model, each with varying degrees of immediate and short-term success 
against Staphylococcus aureus biofilms.  A second study was conducted to determine the 
in vitro anti-bacterial and anti-biofilm properties of Chitosan/Dextran (CD) gel, a novel 
chitosan-based product with remarkable mucosal healing and haemostatic properties. 
 
Methods 
Three alternative anti-biofilm treatments: Mupirocin, CAZS (Citric Acid Zwitterionic 
Acid) and Gallium Nitrate were evaluated in a prospective randomized controlled single-
blinded trial using a previously established sheep biofilm model of CRS. The sheep 
mucosal samples were analyzed for presence of S. aureus biofilms using BacLight staining 
and CLSM, and the degree of biofilm involvement was determined using FISH 
(Fluorescence In-Situ Hybridization).  
The MIC/MBC values for CD gel and its constituents were determined by macro-dilution 
methods described by Jorgensen et al.[1]. Established in vitro biofilms grown from   5 
common CRS pathogens (ATCC strains and clinical isolates) were subjected to treatment 
by CD gel and its components (chitosan and dextran). A 96-well micro-titre crystal-violet 
staining method described by O’Toole and Kolter [2] was used to determine the anti-




Following 8 days of inoculation with S. aureus, all treatment groups in the sheep biofilm 
model showed a statistically significant reduction in biofilm surface coverage compared to 
no treatment. Importantly, sheep frontal sinuses treated with twice-daily mupirocin flushes 
for 5 days showed almost negligible biofilm growth after the follow-up period of 8 days 
(0.84% ± 1.25% surface area coverage per visual field). 
The overall data from the in vitro studies suggest that CD gel has marked anti-microbial 
activity against planktonic and biofilm-forming bacteria. It was inhibitory and 
bacteriocidal at sub-clinical concentrations (25mg/mL) for all bacteria tested except for E. 
coli. When tested against a nutrient-free environment as well as a positive growth control, 
bacteria were essentially unable to grow in its presence. 
 
Conclusion 
Recalcitrant CRS is a difficult condition to manage and its pathogenesis has been closely 
linked to the presence of bacterial biofilms. Using a standardized biofilm sheep model of 
CRS, regular treatment with mupirocin flushes over a 5 day period showed an almost 
complete eradication of biofilms as assessed by mucosal surface coverage, with sustained 
effects over the 8 day period of follow-up.   6 
Equally as efficacious in the in vitro setting, CD gel demonstrated potent anti-bacterial and 
anti-biofilm activity against a number of pathogenic organisms suspected of being 
involved in acute and chronic rhinosinusitis. CD gel’s favourable haemostatic and mucosal 
healing profile posits it as an ideal post-ESS packing material. 
These two topical agents therefore hold promise as effective treatment options in the 
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The aims of this thesis were: 
 
 
1.  To evaluate the efficacy of potential anti-biofilm treatments in an in vitro and in 
vivo animal model of Chronic Rhinosinusitis (CRS). 
 
2.  To implement the use of various modes of bacterial-biofilm detection to confirm 
and quantify the anti-biofilm effect. The modes of biofilm detection include 
LIVE/DEAD cell viability staining (Baclight, Invitrogen), quantification of Colony 
Forming Units, Fluorescence In Situ Hybridization (FISH) staining and Confocal 
Scanning Laser Microscopy. 
 
3.  In an in vivo sheep model of CRS, to determine the potential anti-biofilm efficacy 
of the novel topical treatments: Citric Acid Zwitterionic Surfactant (CAZS), 
Gallium Nitrate, and Mupirocin. 
 
4.  To evaluate the potential anti-biofilm efficacy of a novel Chitosan/Dextran (CD) 
gel, and document its in vitro anti-microbial profile. 
 
5.  To utilize established and reliable in vitro and in vivo models to grow and detect 
bacterial biofilms in order to achieve the aims outlined. 









INTRODUCTION   16 
Chronic Rhinosinusitis (CRS) 
 
Definition and Disease Burden 
 
CRS is a debilitating disease of the sino-nasal epithelium characterized by persistent 
inflammation, with bacterial colonization and infection. In 2003, the Chronic 
Rhinosinusitis Task Force defined CRS as having the status of: continuous signs or 
symptoms for more than 12 weeks and identification of signs of inflammation on anterior 
rhinoscopy, endoscopy or imaging[3]. According to the National Centre for Health 
Statistics, 29.2 million adults in the United States were diagnosed with chronic 




CRS can have a chronic, recalcitrant course often requiring multiple courses of antibiotics 
or surgical procedures or both. Despite its high prevalence and the severe socio-economic 
burden it places on society, its pathogenesis is yet to be clearly defined. Current 
hypotheses include the role of super-antigens, abnormalities of the inflammatory cytokine 
cascade, abnormal cell-mediated immune responses, and protracted osteitis of the sinus 
walls. Recent evidence has emerged demonstrating the presence of bacterial biofilms on 
the mucosa of patients with CRS, which suggests that biofilms may play a role in the 
pathogenesis of this condition.   17 
Bacteriology of CRS 
 
The pathogenesis of CRS is likely to be bacterial in origin. The bacterial profile of acute 
rhinosinusitis (ARS) is very different to that of chronic rhinosinusitis. This is due to the 
difference in physiological environment of each condition. As chronicity develops, the 
aerobic and facultative species are replaced by anaerobes. Whereas ARS is associated with 
aerobic organisms (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis), the organisms predominantly isolated from CRS patients are Staphylococcus 
aureus and anaerobes (Prevotella, Fusobacterium and Peptostreptococcus spp)[4]. In our 
department, S. aureus is the most commonly isolated organism cultured from the mucosal 
swabs of CRS patients. 
Cultures of individuals with CRS not responding to surgery have shown higher than usual 
incidences of Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus 
pneumoniae, and Haemophilus influenzae [5, 6]. 
 
Clinical Management of CRS 
 
The principles of management of CRS are to restore normal mucociliary clearance by 
enlarging the sinus ostia and to remove the offending organism and the underlying mucosal 
edema by surgical irrigation, debridement and post-operative medications. This would 
involve endoscopic sinus surgery (ESS) and courses of antibiotics or topical 
corticosteroids. 
It has been shown that a correlation exists between the in vitro biofilm-producing capacity 
of bacterial pathogens and unfavourable clinical evolution after ESS[7], suggesting that   18 
biofilm-producing capacity may play a role in the pathogenesis of CRS. A comprehensive 
assessment by the representatives of five professional otorhinolaryngologic societies in 
2004 suggested that total eradication of infection in patients with CRS would require the 
mechanical removal of such biofilms to adequately manage the disease[8]. 
 
Bacterial Biofilms 
Definition of Biofilms and Current Concepts 
 
There has been an increasing body of research over the past decade on bacterial biofilms[7, 
9-14]. Biofilms are a microbially derived sessile community characterized by cells that are 
irreversibly attached to a substratum or interface or to each other, are embedded in a matrix 
of extracellular polymeric substances that they have produced, and exhibit an altered 
phenotype with respect to growth rate and gene transcription[15].  
Figure 1 is a Scanning Electron Microscope (SEM) image of a biofilm. The arrows 
indicate individual cocci embedded within the exopolymeric substance (EPS) matrix. 
Bacteria in the biofilm phenotype are less metabolically active and more resistant to 
common antimicrobials. Bacteria live in biofilms as a major and possibly preferred form, 
and represent greater than 90% of biomass in many environments[16]. 
   19 
Figure 1. Scanning Electron Microscope (SEM) image of a biofilm. Arrows indicate 
individual bacteria embedded within the EPS matrix[17]. 
 
   20 
Ultrastructure of Biofilms 
 
Biofilms consist of single cells and micro-colonies, all embedded in a highly hydrated, 
predominantly anionic exopolymeric substance (EPS) matrix. They are not a homogeneous 
monolayer of microbial cells on a surface, but rather, heterogeneous in both time and 
spatial arrangement. The cells within the deeper layers of the biofilm ultrastructure are 
exposed to lower oxygen tensions, and are less metabolically active. Phenotype studies 
have revealed that these areas within the biofilm are hypoxic and hypo-metabolic[18]. 
The bacterial micro-colonies are connected by well-developed channels, which convey 
fluid and nutrients by connective flow[19].  Polysaccharides (carbohydrate-rich polymers) 
and proteins constitute the majority of the EPS matrix. DNA and extracellular genetic 
material have also been demonstrated within the EPS[20], as well as devitalized bacterial 
contents[21].  
The adaptive ability afforded by heterogeneous populations of bacteria within the EPS 
means that there is no one common biofilm structure. The adaptive response is different on 
inert surfaces as compared to living mucosal surfaces, which are under constant 
modulation by the host immune response[22].  
   21 
Formation of Biofilms 
 
Each pathway of biofilm formation is controlled by a specific cell-signaling system [21, 
23-26]. The first stage involves “Attachment” and it is during this period that genetic 
signals are dispatched from bacteria to initiate the phenotypic changes necessary for 
adherence. Next, the second stage of “Adhesion and Aggregation” involves the grouping 
and bonding of small numbers of bacteria by structural changes in their cell walls. In high-
shear environments such as on mucus-covered surfaces, the benefits of adhesion and 
aggregation allow successful penetration and attachment to the muco-ciliary blanket for the 
third stage, “EPS matrix formation”. Currently, no explicit “on-off” signals have been 
identified for this crucial step. It is believed to be multi-factorial in nature. The fourth stage 
of “Growth and Maturation” involves the redistribution of bacteria away from the 
substratum and the proliferation of flow channels, formation of metabolic niches and 
micro-colonization by phenotypic variants. Finally, as the biofilm matures the 
“Detachment” [27] phase is reached, characterized by embolization (by active or passive 
mechanisms) of the biofilm colony itself or loosely aggregated planktonic bacteria. A 
recent study of P. aeruginosa biofilms, using immunohistochemical staining and CLSM 
imaging, investigated the presence of an EPS matrix component (Psl) and it’s role in the 
dispersion of planktonic bacteria. Observing the pattern of Psl presence in each stage of 
biofilm development, Ma et. al [27] demonstrated its early influence in maintaining the 
architectural integrity of the matrix in the Attachment and Maturation stages, but also its 
absence in the centre stalk of the mushroom-like micro-colonies as they mature to create 
matrix cavities filled with detached bacteria, ready for dispersal and embolization. This 
leaves the remainder of the micro-colony structure intact.     22 
 
Why do bacteria form biofilms? 
 
There are several theories that relate to why planktonic bacteria prefer the biofilm mode of 
existence.  
One theory suggests that bacteria form biofilms as a defense mechanism. Various factors, 
such as the protection conferred by the EPS matrix, the genetic heterogeneity between 
biofilm micro-colonies, or their slow growth rate, are conducive to their survival in 
physiologically inhospitable conditions. Biofilms formed in these areas can withstand 
physical sheer forces, nutrient deprivation, pH changes, oxygen radicals, disinfectants, and 
antibiotics, as well as host immune defense mechanisms. Certain bacterial strains have 
evolved to switch on transcription of genes required for EPS synthesis in response to 
certain environmental stimuli upon host entry, before the immune system mounts a specific 
attack[28]. For example, physiological conditions such as iron-deprivation or osmotic 
stress, can induce the expression of genes encoding proteins that synthesize EPS in 
staphylococci and enterococci as an early defensive response[29]. 
Another theory suggests that biofilm formation occurs as a mechanism for bacteria to 
remain fixed in a favourable niche. Colonization in a nutrient-rich site would promote 
survival of the species. This is evidenced by the production of an impressive array of 
bacterial surface proteins (microbial surface component recognizing adhesive matrix 
molecules- MSCRAMMs) that are present in the initial stages of biofilm attachment, and 
help bacteria adhere to the host surface upon detection of nutrient sources. These 
molecules are particularly abundant in S. aureus biofilms, and include clumping factors A 
and B, fibronectin binding factors and collagen binding proteins[30].    23 
Another hypothesis suggests that biofilm bacteria exhibit cooperative behaviour to provide 
survival benefits as a community to maintain overall sustainability, through specialization 
of function[31], phenotypic differentiation, division of metabolic burden and programmed 
cell death[32]. This theory has recently been tested in mathematical modeling of biofilm 
systems [33] and appears to fit with mainstream theories of evolution. 
 
 
Unique Properties of Biofilms 
 
Many of the processes involved in biofilm formation are motivated by the requirement for 
survival and resistance against external destructive forces. 
Biofilm-mediated infections are often chronic, are rarely resolved by host defenses, are 
characterized by acute exacerbations, and the microbial community is often difficult to 
define and culture. It is the organized functional heterogeneity that holds the key to the 
distinct life cycle of biofilms, and contributes to the difficulty of targeting therapies against 
these unique structures. The ultra-structure of biofilms also plays a significant role in 
protecting their survival. Surprisingly, bacteria preferentially form biofilms in high-shear 
environments in natural and environmental systems[15], whether the surface is rough or 
smooth, their EPS producing a highly visco-elastic structure. This is perhaps the reason 
why, in most recalcitrant biofilm-mediated diseases, complete surgical excision of the 
bacteria along with the surface to which it has adhered is required for definitive treatment. 
The EPS matrix, which encases the micro-colonies of biofilm bacteria, is composed of 
polysaccharides (carbohydrate-rich polymers) and proteins. Nucleotides or extracellular   24 
DNA have also been demonstrated within the matrix, consistent with the concept of gene 
transfer in cell-to-cell signaling. 
Established biofilms can tolerate antibiotic concentrations of up to 1000 times that needed 
to kill its planktonic counterparts. The precise mechanism of antibiotic resistance in 
biofilms remains unclear and is thought to be multi-factorial.  
Earlier research into the antibiotic resistance of biofilms focused on the EPS matrix, 
suggesting that it retarded the diffusion of antibiotics or prevented the migration of 
neutrophils. It is plausible that the accumulation of beta-lactamases within the matrix could 
deactivate beta-lactam antibiotics [34] and infiltration of positively charged antibiotics 
(aminoglycosides) could be retarded by the negatively charged EPS matrix[18]. But more 
recent data reveal that antibiotics are able to penetrate the biofilm matrix unimpaired[35]. 
Other studies demonstrate the presence of inflammatory cellular elements (phagocytes and 
activated polymorphonuclear cells) deep within the biofilm[36].  
 
   25 
Biofilms and Chronic Disease 
 
In the last two decades there have been numerous studies demonstrating the presence of 
bacterial biofilms in chronic diseases. Chronic diseases in which biofilms have been 
implicated are otitis media with effusion[37], cystic fibrosis[38], cholesteatoma[39] and 
chronic tonsillitis[40]. Biofilms have also been isolated on prosthetic devices such as 
central venous catheter tips, urinary catheters, orthopedic prostheses, tracheostomy 
tubes[14] and tympanostomy tubes[41]. The detection of biofilms in chronic diseases, in 
which there is continual presentation of antigens (such as bacterial cell surface antigens 
and exotoxins) and persistent induction of the chronic inflammatory response, have made 
their implication in the pathogenesis both plausible and attractive. 
It is the planktonic form of bacteria that is responsible for the patient’s systemic response 
and manifestation of acute symptoms. The biofilm serves as a nidus of infection, 
periodically shedding planktonic cells to stimulate the body’s defense mechanism and 
provoke cellular and humoral immune responses[42]. 
The clinical course of Chronic Rhinosinusitis (CRS) often shares this profile and bares the 
hallmarks of biofilm-mediated disease. 
   26 
Biofilms and CRS 
 
Recent studies have demonstrated biofilm morphology in mucosal samples from human 
CRS patients[10, 12, 13, 22, 43-45]. Using strict morphological criteria, Sanclement et al 
utilized Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy 
(TEM) to demonstrate biofilm morphology on mucosal samples in 80% of their CRS 
patients and none of their control patients[12]. Other studies have used indirect methods of 
determining biofilm presence by demonstrating the in vitro biofilm-forming capacity of 
bacteria cultured from the mucosal surface of their CRS patients.  Bendouah et al[7] 
represents the only study to link biofilm factors to poor clinical outcome. However, the 
bacterial strains investigated were cultured in vitro to determine their biofilm-forming 
capacity, and hence do not represent the phenotypes located within the biofilms. 
Fluorescence In Situ Hybridization (FISH) was used by Sanderson et al[45] to determine 
the presence of bacterial biofilms on the sinus mucosa of CRS patients. In this study, the 
mucosal samples were FISH tested for the presence of S. pneumoniae, S. aureus, H. 
influenza and P. aeruginosa biofilms. There was evidence of bacterial biofilms in 14 of the 
18 CRS patients examined, with some specimens exhibiting poly-microbial biofilms. 
Interestingly, evidence of H. influenza biofilm was found in 2 of the 5 control patients, 
representing non-pathogenic colonization of the sinonasal mucosa in the asymptomatic 
patients. No correlation was found between the biofilms present on the sinus mucosa and 
the cultures taken at the time of surgery, further confirming the biofilm paradigm as a 
difficult bacterial entity to culture. This finding also explains why they are so recalcitrant 
to conventional culture-directed antibiotic therapy.   27 
In our department, Confocal Scanning Laser Microscopy (CSLM) was used as a non-
invasive, nondestructive technique to analyze fresh mucosal tissue samples for the 
presence of biofilms. Samples were assessed for bacterial biofilms as determined by the 
identification of immobile, irreversibly attached, live bacteria of appropriate size (0.5-2µm 
diameter) and morphology, existing in clusters and towers of micro-colonies. Of the 
patients who had CRS, 79% had undergone previous surgery and of these revision cases, 
50% demonstrated biofilms under CLSM examination[44]. The high incidence of biofilm 
involvement in the refractory cases further implicates biofilms as a contributing factor to 
the persistence of the disease, especially when the infective nidus is not completely 
eradicated with surgery.  
The frequency of biofilm presence in the CRS patients was 44.7%, and none in the control 
patients. This figure was considerably lower than those determined in previous studies of 
biofilms in CRS patients. The discrepancy may be explained by the difference in detection 
modalities used, patient population or sampling error. However, CLSM was a modality 
shown to offer many advantages both in this model and in a previous animal model for the 
analysis of biofilms in fresh tissue[17]. With CLSM, the mucosal specimens were 
processed fresh within 20 minutes of harvest. There were no dehydration or fixative agents 
used, thus conserving the architectural features of the biofilm structures. The procedure 
used cellular probes, making the bacterial micro-colonies more distinguishable against 
native mucosal structures. This, together with the freedom to analyze much larger samples 
compared to electron microscopic methods, makes CLSM a reliable technique for 
detecting bacterial biofilms. 
   28 
Detection of Biofilms 
 
The bulk of research involving biofilms in sinusitis has relied heavily on electron 
microscopy, in particular scanning electron microscopy (SEM) (Figure 1). This technique 
has been used to examine biofilms in human infections[9, 12, 46] and on biomedical 
devices[46, 47]. SEM requires the use of solvents to gradually dehydrate the specimen 
because the vacuum used with the electron beam is not compatible with hydrated tissue. 
The samples are dehydrated by a graded series of 70-100% ethanol, and then critical point 
dried in CO2. The dehydration procedures result in significant distortion of architecture and 
artifact, particularly in mucosal tissue. Since the EPS matrix is composed of 95% water, 
the distortion would make SEM images not truly representative of the complex three-
dimensional structure of biofilms. Another disadvantage of SEM is the fact that it only 
images the surfaces of tissues, thereby missing the majority of micro-colonies embedded 
deep within the matrix. Also, mucus and biofilm matrix are both composed of long-
chained polysaccharides, and are not dissimilar in appearance on SEM analysis. This may 
result in incorrect identification of biofilms in mucus-filled specimens. Ha et al 
demonstrated this hypothesis when CSLM failed to confirm the presence of biofilms in 14 
of 34 sheep mucosal samples previously shown to contain biofilms on SEM[17].  
 
Transmission electron microscopy (TEM) of mucosal tissue prepared by the cryofixation 
technique[12] may circumvent the issue of distortion artifact, but only isolated cross 
sections of mucosa can be examined at any one time (Figure 2).  
Although the EPS matrix is relatively preserved and deeper biofilms can be imaged using 
this technique, the restriction to single planar views limits TEM’s capacity as a searching 
tool. This is because biofilms can be scattered at multiple mucosal sites and levels.   29 
 
Figure 2. TEM (Transmission Electron Microscopy) image of a biofilm[17]. 
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BacLight and CSLM 
 
CSLM imaging (Figure 3) incorporates the use of nucleic acid probes. These probes 
specifically stain cellular structures and the exopolymeric substance matrix, making them 
distinguishable from mucus. The tissue preparartion for CSLM involves a stringent 
washing procedure in sterile milli-Q water to remove planktonic bacteria. Next, component 
A (syto 9) and component B (propidium iodide) of the BacLight LIVE/DEAD kit 
(Invitrogen, Molecular Probes, Eugene, OR) are added to the samples and left to incubate 
in darkness. When used in combination, Syto 9 preferentially stains live cells green and 
propidium iodide preferentially stains damaged or dead cells red (Figures 4a,b). Apart 
from their characteristic biofilm micro-colony arrangement, bacteria can be readily 
differentiated from other cells based on their smaller size (0.5-2µm in diameter) and more 
intense fluorescence (Figure 4c).   31 
Figure 3. Leica SP5 Spectral scanning laser confocal microscope (CSLM), with LAS 
software suite (Leica Microsystems, Wetzlar, Germany). 
   32 
Figure 4a. CLSM image of healthy control stained with BacLight LIVE/DEAD kit (20x 
magnification)   33 
Figure 4b. CSLM image of healthy control stained with BacLight LIVE/DEAD kit (60x 
magnification) 
   34 
 
Figure 4c. CLSM image of mucosa containing S. aureus biofilms stained with BacLight 
LIVE/DEAD kit. The organized cluster of smaller, intensely fluorescent green cells 
represent live bacteria within a biofilm (centre of image).   35 
FISH and CSLM 
 
Fluorescence In Situ Hybridization  (FISH) allows the differentiation of microbial 
organisms within a biofilm, which sets it apart from the aforementioned detection 
modalities. The technique is based on the binding of fluorescently labeled molecular 
probes to specific RNA sequences of the target microorganism. Recently, Peptide Nucleic 
Acid (PNA) probes have been developed as part of a rapid identification assay for 
organisms such as S. aureus[48].  
Peptide nucleic acid (PNA) molecules are pseudopeptides that obey Watson-Crick base 
pairing rules for hybridization to complementary nucleic acid targets (RNA and DNA). As 
a consequence of their uncharged, neutral backbones, PNA probes exhibit favourable 
hybridization characteristics for highly structured targets such as rRNA. In addition, the 
relatively hydrophobic character of PNA compared to other classes of DNA 
oligonucleotides allows better penetration of the hydrophobic cell wall of the bacteria. 
The PNA FISH assay uses a PNA probe that targets a species-specific region of the 16S 
rRNA of S. aureus. Once it is bound to the S. aureus, visualization of the target 
microorganism is then made possible by CSLM, revealing multiple clusters of bright 
fluorescent cocci in multiple fields of view (Figure 5). As the EPS matrix also contains 
segments of RNA from cell breakdown and horizontal gene transfer, a surrounding haze of 
less intensity is an expected finding in the visualization of biofilms via CSLM.   36 
Figure 5. Typical CLSM image of sheep mucosa containing S. aureus biofilms 
fluorescently labeled with Alexa-488 PNA FISH probe (AdvanDx, Woburn, MA, USA) 
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Using the FISH /CSLM assay, Sanderson et al was able to demonstrate bacterial biofilms 
on the sinus mucosa of CRS patients, and H. influenzae colonization of the mucosa of non-
CRS patients[45]. Although theoretically possible, multiple probes can be used 
simultaneously on the same mucosal sample to demonstrate polymicrobial involvement. 
However, because of the laborious nature of the hybridization process and the cost of FISH 
probes, it would be more time-efficient and cost-efficient to focus on predominant 
pathogenic species. 
The PNA FISH assay kit provided by AdvanDx (Woburn, MA, USA) has been validated 
in the rapid identification of S. aureus in blood cultures. Although the kit was originally 
designed to hybridize with S. aureus organisms in thinner blood smears, the same 
protocols were used to detect S. aureus biofilms in mucosal samples in the study described 
in this thesis. Mucosal tissue penetration of the laser used in CSLM may not have detected 
biofilms embedded in thicker sections of tissue, but this was an accepted limitation of the 
study. Thus, randomization of tissue sampling was used to minimize the impact of this 
factor.      
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Animal Model of CRS 
 
Advantages of the sheep model 
The sheep is an ideal animal model for the investigation of bacterial biofilms. Previously 
our department has successfully utilized the sheep CRS model to investigate various novel 
haemostatic agents and wound healing agents that impact on endoscopic sinus surgery in 
humans. More recently, Ha and Psaltis et al developed an ideal sheep frontal sinus CRS 
model for the study of bacterial biofilms that was deemed appropriate for this study[17]. 
Other possible animal models were explored but were not suitable technically or 
practically.  
Dogs possess similar sinus structure to humans but were not available for ethical reasons. 
Pigs are dissimilar in sinus alignment and their turbinate structure makes them impractical 
for endoscopic surgery. New Zealand white rabbits have been used in literature[11, 49] to 
investigate biofilms, but have the disadvantages of smaller sinus cavities and are not 
certain to be free from Pasteurella infection. 
Previous studies[11] have used the rabbit maxillary sinus, which requires an external 
approach to access. The open external approach requires an external incision and raising a 
periosteal window. This exercise would potentially disrupt the sinus mucosa within the 
maxillary sinus and contaminate the inoculation process. Additionally, the use of 
endoscopic nasal techniques cannot be replicated in these smaller animals.   39 
With regard to sinus disease, the sheep possess a similar spectrum of conditions to humans. 
This includes allergic rhinitis, sinusitis and nasal polyposis. Their sinus mucosa is similar 
to humans histologically. Their sinus alignment and long snouts are suitable for 
instrumentation with slightly modified ESS equipment (Figure 6). The sheep frontal sinus 
is superficially located, making trephination for the application of topical therapies and 
mucosal harvesting an easy process (Figure 7). 
Our department has accumulated vast experience with the sheep model and we have access 
to the facilities to support such a model[17, 50-53]. Our observation has been that the 
sheep are able to tolerate long operative procedures and recover from the anesthesia 
quickly.       40 
Figure 6. Modified endoscopic instruments. (a) Storz 5mm straight 26cm telescope (b) 
4mm straight 18cm telescope (c,d) suction tubes with and without grip plate (e)Blakesley 
nasal scissors (f) through-biting forceps (g) straight forceps (h) 45˚ upturned nasal forceps. 
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Figure 7. CT scan image of sheep sinuses in the (a) coronal and (b) sagittal planes. 
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It is difficult to achieve effective biofilm killing concentrations in sinonasal mucosa 
without systemic side effects, especially when antimicrobial agents are delivered via the 
oral or parenteral route. The mounting evidence implicating bacterial biofilms as a 
mediator of recalcitrant CRS has generated multiple experimental concepts in its treatment, 
each with varying rates of success. Surmounting the reduced susceptibility of biofilm 
bacteria and robustness of biofilm-mediated infections has been the focus of many in vitro 
and in vivo experiments in recent literature.  
Topical administration of antibiotics to the sinus mucosal membranes by either nasal 
irrigation or nebulizers is one novel approach that would enable higher local inhibitory 
concentrations to be achieved at the site of biofilm infection. This would be coupled with 
the advantages of low serum levels and lower risk of systemic side effects. 
 
In vitro investigation of anti-biofilm treatments 
 
Desrosiers et al explored the efficacy of topical moxifloxacin in inhibiting biofilm 
formation as well as eradicating established biofilms in vitro[54]. This group used colony 
forming unit (CFU) counts as a measure of bacterial viability in biofilms exposed to   43 
increasing concentrations of moxifloxacin. Although there was no effect on mature 
biofilms at sub-MIC levels (Minimum Inhibitory Concentration), the authors reported a 
dose-dependent reduction in CFU counts at supra-MIC levels with a maximal reduction at 
1000X MIC. 
Chiu et al evaluated the effect of topical tobramycin delivered through an indwelling 
catheter as a regular lavage, into the maxillary sinuses of white rabbits infected with 
mature P. aeruginosa biofilms[49]. The biofilm incubation period was seven days, and the 
sinus lavages occurred on alternate days for seven days. At doses of 400X MIC (400µg/L), 
tobramycin was more effective than saline in reducing CFU counts propagated from the 
lavage collection fluid. However, when cultures were performed from the actual harvested 
mucosal samples of the sinus, there appeared to be no difference in viable bacterial counts, 
indicating persistence of bacterial colonization in situ by the attached biofilms. This is 
despite a reduction in the washed-out planktonic load. 
Ha et al measured the in vitro efficacy of mupirocin against eight clinical isolates and one 
ATCC strain of S. aureus using the crystal violet staining model for bacterial biofilms[55]. 
At concentrations of 7.81 and 125µg/mL, mupirocin was able to eradicate 50% of biofilms 
after 1 hour of exposure. After 24 hours, 90% of the in vitro biofilms were eliminated. 
Mupirocin is an antibiotic that has broad anti-staphylococcal activity and is stable within 
the sinus mucosal membrane. It has very little cross-resistance and has low systemic 
uptake. Mupirocin, mixed in solution with Ringer’s lactate, was used by Uren et al in a 
prospective clinical trial to treat surgically recalcitrant CRS patients from a tertiary 
rhinological treatment centre[56]. Powdered mupirocin was reconstituted into solution at a 
concentration of 0.05% with Ringer’s lactate and used as a bi-daily nasal lavage in S. 
aureus-positive CRS patients for a period of 3 weeks. There were significantly favourable   44 
changes seen both on endoscopic examination and noticeable symptomatic improvement 
after the treatment period. 
Given the promising results both in the in vitro and clinical setting, and its safety profile, 
administering topical mupirocin should be considered as an alternative approach to 
managing surgically resistant CRS. Although effective in eradicating in vitro biofilms, Ha 
and Uren et al demonstrated a time-dependent killing effect of mupirocin, with results 
trending towards a greater rate of biofilm eradication and symptom control by regular 
dosing (at least 24 hours and up to a period of 3 weeks)[55, 56]. This is to ensure that any 
remaining nidus of bacteria cannot re-adhere and re-grow to develop into further biofilms.  
Such continuous antimicrobial treatment is certainly achievable with regular nasal 
irrigation regimes. With this concept in mind, impregnation of mupirocin into post-ESS 




Using the Calgary biofilm detection assay, the loop diuretic furosemide was tested by 
Cross et al against P. aeruginosa biofilms and showed a 50% reduction in biofilm size at a 
concentration of 10mg/mL[57]. Although furosemide was not evaluated as an eradication 
agent, the results suggest that it could potentially be used as an adjunct to antimicrobials to 
destabilize biofilm structures and assist in their eradication. 
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Surfactants 
 
Chemical surfactants are amphiteric molecules that act to modulate the way other 
molecules behave at interfaces and in solution. The amphiteric properties of surfactant 
allow it to be solvent in both water and organic substrates. By altering the mucus-mucosal 
surface interface, chemical surfactants have the potential to act as mucoactive agents to 
assist with mucociliary clearance and prevent biofilm adherence. Additionally, surfactants 
can disrupt cell membrane integrity, increase cell membrane permeability causing 
metabolite leakage, and can interfere with cell membrane exchange functions. This would 
ultimately disrupt bacterial cell survival mechanisms to control biofilm growth. 
Chiu et al explored the use of surfactants as agents to disrupt biofilm integrity in a 
prospective, non-randomized clinical study of post-operative ESS patients[58]. After self-
irrigating their nasal cavities with 1% baby shampoo diluted in normal saline for a period 
of 4 weeks, the subjects reported a 46.6% rate of improvement in their Sinonasal Outcome 
Test 22 scores and a 63% rate of improvement in their olfactory function along with 
endoscopic evidence of healthier mucosal function (decreased rate of mucosal edema and 
polypoid degeneration). 
Despite the theoretical advantage of chemical surfactant, the removal of adherent biofilms 
would also require disruption of the EPS matrix that confers protection to the bacterial 
micro-colonies. Strong calcium-ion bridges that bind the long polymeric chains in the EPS 
matrix are partially responsible for the integrity of biofilm structures. The disruption of 
these “cross-links” by a sequestering agent, citric acid, followed by dissolution of the 
unbound chains by surfactant, was a strategy posited by Desrosiers et al[59]. This group 
examined the effect of CAZS -citric acid and zwitterionic surfactant (caprylyl sulfobetaine) 
-on 3 day-old in vitro S. aureus and P. aeruginosa biofilms grown in drip flow reactor   46 
(DFR) systems to mimic the low shear environment in which robust biofilms flourish. 
Along with static CAZS treatment, hydropressure, at 31.4 psi, was also examined as a 
delivery method for the CAZS in the in vitro experiment. Based on the CFU counts 
obtained from viable bacteria cultured from the DFR slides, both static CAZS and 
hydrodynamically treated biofilms showed a reduction in bacterial load. However, 
hydrodynamic treatment with saline also produced a reduction in biofilms, but to a lesser 
extent (2.3 log reduction in S. aureus biofilms for saline, as compared to 2.5 log reduction 




Hydropressure has been used with success in orthopedic surgery as a method of 
mechanically removing biofilms from metallic surfaces prior to prosthetic implantation[60, 
61]. The effect of jet lavage applied to a surface lined with mature biofilms can reduce the 





Iron (Fe) metabolism is integral to the pathogenesis of bacterial infection, particularly 
chronic infection[63]. In almost all pathogens, Fe is essential for the development and 
functioning of key enzymes such as those involved in DNA synthesis and electron 
transport. A high Fe concentration in situ promotes the growth of bacterial biofilms, 
because high Fe levels are required for the formation of cell clusters early in biofilm   47 
development and maturation[64]. Many host defense mechanisms result in the 
sequestration of Fe to limit the spread of bacterial growth by lowering the Fe concentration 
locally. Data from a number of laboratory studies have shown the importance of Fe 
limitation in blocking acute infection from various bacterial species[63, 65]. Fe 
metabolism is a major vulnerability of pathogenic bacteria. Gallium (Ga
3+) nitrate has been 
used to exploit the vulnerability because this transition metal is nearly identical in ionic 
radius to Fe
3+, effectively acting as a “Trojan Horse” to disrupt Fe-dependent processes. 
Unlike Fe
3+, Ga
3+ cannot be reduced, and it is the sequential oxidation and reduction 
reactions that are critical for many of Fe’s biological functions[66].  
 
Importance of Mucosal Injury, Restoration of Normal Mucociliary Clearance in 
treating CRS 
 
With any therapy, the mucosal epithelial functioning must be preserved because adequate 
mucociliary clearance remains the best treatment to prevent CRS. 
If it is clear to the clinician that conventional systemic antimicrobial and anti-inflammatory 
agents have not adequately controlled the disease, then surgical ventilation of the involved 
paranasal sinuses is the mainstay of treatment. This involves a combination of restoring 
mucociliary clearance and surgically removing bacterial biofilms from the sinonasal 
mucosa to prevent future exacerbations caused by re-infection by a viable remnant nidus of 
bacteria.  
Post-operative mucosal healing is integral to the control of CRS symptoms. Patients with 
rhinosinusitis recalcitrant to standard medical and surgical therapy often show rapid 
disease recurrence after an initial response to antibiotics. Surgically recalcitrant CRS 
patients represent some of the most challenging patient cohorts in any tertiary rhinology   48 
practice. Numerous studies have tested the adequacy of post-ESS packing materials to 
inhibit bleeding, the development of adhesions, and positively impact on the healing of the 
ciliated mucosal tissue. Adhesions remain the main cause of failure in ESS, and poor 
mucosal healing is a significant contributor to this failure. This is particularly relevant to 
more radical surgery such as the modified endoscopic Lothrop procedure. Maintaining 
patency of the neo-frontal ostium and eradication of infection, are paramount to ensuring 
the success of the procedure. In examining mucosal samples of recalcitrant CRS patients 
requiring multiple ESS procedures, Psaltis et al identified the presence of biofilms in this 
particular group by CSLM criteria[44]. 
Very few studies have explored the effect post-operative packing materials may have on 
the re-generation of bacterial biofilms. Packing materials with anti-biofilm properties may 
offer the ideal medium for exerting sustained antimicrobial effect on remnant biofilms or 
prevent further re-growth of bacteria by providing a hostile anti-biofilm environment 
within the sinonasal cavity. 
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Post FESS packing material 
 
Chitosan and Mucosal Healing Studies 
 
Chitosan is a natural polymer obtained from chitin, which is the structural element in the 
exoskeleton of crustaceans and squid. It has been studied extensively for its potent 
haemostatic properties, but has recently been investigated as an anti-adhesion agent in 
general surgery[67, 68]. When combined with dextran derivatives, chitosan forms cross 
links to form a mucoadhesive gel (Chitosan-Dextran or CD gel). Bleeding and wound 
healing are intimately related. The initial inflammatory phase of wound healing involves 
haemostasis and clot formation. The injured tissue induces fibroblast migration, resulting 
in collagen deposition and fibrous adhesion formation. Athanasiadis et al studied the effect 
of CD gel on full thickness mucosal injuries created in the lateral nasal wall of sheep, 
specifically observing the effect on mucosal re-epithelialisation, re-ciliation and ciliary 
beat frequency[52]. The most significant effect on wound healing was CD gel’s ability to 
enhance the recovery of epithelium, reflected in the significantly greater degree of re-
epithelialisation and percentage surface area that was re-ciliated 28 days post-injury. These 
parameters were compared to other commercially available haemostatic agents 
recombinant tissue factor (rTF), poly-ethylene glycol (“SprayGel”) and saline control. 
Overall, CD gel demonstrated a superior wound healing profile with 70% re-
epithelialisation and 62% reciliation of surface area 28 days post-application. 
CD gel is a novel and unique synthetic gel that can be used as a post-ESS mucoadhesive 
dressing, but it also has the ability to dissolve over a period of 7 to 9 days. Its ability to   50 
adhere to the sinonasal mucosa makes it an ideal carrier for a number of antibiofilm agents. 
Previous studies have shown that chitosan itself may have anti-biofilm properties[69-72]. 
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Chronic Rhinosinusitis (CRS) has a complex pathogenesis. Bacterial biofilms have been 
associated with poorer outcomes post endoscopic sinus surgery (ESS). A novel absorbable 
chitosan dextran gel has been shown to reduce the rate of post-ESS adhesion formation, 
bleeding and may have anti-biofilm properties. 
 
Method 
The antimicrobial profile for chitosan/dextran (CD) gel and its constituents were 
determined using a macrodilution method of evaluating MIC/MBC, zones of inhibition of 
growth, colony-forming units for evaluation of microbial growth activity.  The 
susceptibility tests were performed for common CRS pathogens as well as clinical isolates. 
The antibiofilm effects of the test agents were assessed using a 96-well micro-titre crystal 
violet staining method described by O’Toole and Kolter. Only organisms of biofilm-
forming capacity were included in the analysis. 
 
Results 
All bacterial strains tested were susceptible to dextran. CD gel was both bactericidal and 
inhibitory to all strains except for E. coli. Overall, dextran exhibited the greatest effect on 
growth inhibition with a slightly lesser inhibitory effect demonstrated by CD gel on zone 
of inhibition analysis and microbial growth activity tests. More importantly, neither CD gel 
nor its constituents promoted growth of tested strains compared to no-treatment. At 
subclinical concentrations (25mg/mL) CD gel produced significant reduction in biofilm 
formation for all tested bacteria apart from S. pneumoniae.   91 
 
Conclusion 
Overall, CD gel demonstrated marked antimicrobial activity against a wide range of 
planktonic and biofilm forming bacteria. The data support randomized clinical trials that 
demonstrate CD gel’s remarkable ability to reduce the appearance of infection in the nasal 
cavity compared to control. This, combined with its unique mucosal healing properties, 
posits CD gel as a useful absorbable nasal packing material post-ESS. 




Chronic rhinosinusitis (CRS) has a complex pathophysiology with a number of possible 
aetiologies postulated.  
These include bacterial biofilms[43], staphylococcal superantigens[96], fungus[97], 
abnormal cell-mediated immune responses and abnormal cytokine cascades[98], prolonged 
sinonasal osteitis[99] as well as anatomical predisposition[100, 101]. These aetiologies are 
thought to result in mucosal inflammation and increased secretions that can block sinus 
ostia and drainage outflow tracts. The environment is then ideal for secondary bacterial 
growth and resultant mucosal trauma which propagates the cycle of oedema, thickened 
mucosa and disruption of the sinonasal mucociliary system[102]. 
 
In acute sinusitis, organisms such as Haemophilus influenzae, Streptococcus pneumoniae, 
and Moraxella catarrhalis are commonly isolated[103]. Staphyloccocus is one of the most 
commonly cultured organisms from CRS patients’ although it is not necessarily pathogenic 
in all instances[104, 105].  In chronically infected sinuses the main aerobes cultured 
include Gram negative bacilli such as H. influenzae, K. pneumoniae, E. coli and P. 
aeruginosa[106]. As the disease process becomes more chronic, the aerobic and facultative 
bacteria are gradually replaced by anaerobes such as Peptostreptococcus species, 
Prevotella, Fusobacterium, Enterobacter species and Bacteroides fragilis[106-109]. 
 
Recently biofilms have been described on the sinus mucosa of patients with CRS[12, 43]. 
Importantly biofilms of Staphylococcus aureus and Pseudomonas aeruginosa have been   93 
found to be associated with a poor prognosis following endoscopic sinus surgery (ESS)[7, 
110].  
 
Recently non-absorbable nasal packing following ESS has been been superseded by 
absorbable packing materials. However, these packs have been shown to be largely 
ineffective in hemostasis and adhesion prevention [111, 112] with some authors suggesting 
that no packing is the best alternative[113]. A recent development of a novel absorbable 
haemostatic chitosan gel has shown promising results in both hemostasis and wound 
healing following endoscopic sinus surgery[114]. 
Chitosan has been reported as having a wide spectrum of antibacterial[115], antiviral[116], 
antifungal[117, 118] and even antibiofilm[71, 119, 120] activity. Use of chitosan has also 
been shown to prevent post operative infection developing in highly contaminated wounds 
in mice[121]. Due to the risk of infection from foreign material being placed in the nose as 
well as possible colonization by pathogenic CRS microbes, the effects of the gel on known 
and potential nasal pathogens warrants investigation. 
 
The aim of this study was to determine the antibacterial and antibiofilm properties of this 
novel Chitosan-Dextran (CD) gel with reference to some well known ATCC strains as well 
as clinical isolates cultured from CRS patients. 
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METHODOLOGY 
 
The minimal inhibitor concentration (MIC) of constituent components of the Chitosan-
Dextran (CD) gel (dextran and chitosan) against bacterial organisms was determined using 
a broth macro-dilution method described by Jorgensen et al [1], modified to suit the 




Chitosan (alone) was prepared fresh by dissolving 0.5g of the sterilized dry product in 
10mL of sterile water 20 minutes before testing. The stock solution of chitosan was added 
to 10mL of broth to give a final stock antimicrobial concentration of 50mg/mL. The 
antimicrobial agents were tested at log2 serial dilutions. From the final stock tube, 1 mL 
was removed and transferred into the next tube containing 1mL of broth. After mixing, 
1mL of this dilution was removed and transferred in the next tube until a final 
concentration of 0.10mg/mL was achieved. The same procedure was repeated for dextran.  




Isolates were inoculated into a broth that would support good growth. Mueller-Hinton 
broth (Oxoid Australia, Thebarton, South Australia) was used for Staphylococcus aureus 
Pseudomonas aeruginosa and Escherichia coli.  CSF broth (Oxoid Australia, Thebarton, 
South Australia) was used for Haemophilus influenzae and Streptocuccus pneumoniae. 
ATCC strains of S. aureus (25923), S.pneumoniae (49619), H. influenzae (49247) and E.   95 
coli (35218) were used for susceptibility testing. One clinical isolate of P. aeruginosa was 
chosen. A few colonies of each isolate grown overnight on agar plates were directly 
suspended in broth until the adjusted turbidity matched a 0.5 McFarland standard. A 
portion of the standardized suspension was diluted 1:100 (10
6 CFU/mL) with broth.  One 
mL of this final inoculum was added to each tube containing 1mL of the diluted compound 
in broth to achieve a final concentration of 5 x 10
5 CFU/mL. Broth without test compound 
was inoculated with bacteria and used as positive growth control. Each tube was incubated 
in air at 35
0C +/- 2 





The MIC was determined as the anti-microbial concentration that visibly inhibited growth 
of the organism, by evaluating the turbidity of each tube’s contents with the unaided eye. 
Assessment of Minimal Bacteriostatic Concentration (MBC) was carried out by sub-
culturing 100 µL from each no-growth tube onto Horse Blood Agar plates (Oxoid 
Australia, Thebarton, South Austrlia) and incubating overnight in air at 35
0C +/- 2 
0C. 
MBC was determined as the lowest dilution showing no growth. 
 
Susceptibility Method by Disk Diffusion 
 
Antibacterial activity using agar diffusion method was performed by inoculating a Mueller 
Hinton Agar plate or Mueller Hinton Agar plus Sheep Blood (Oxoid Australia, Thebarton, 
South Australia) with a 0.5 McFarlands standard of the test organism according to standard 
antimicrobial susceptibility testing procedures[1]. Seven 5 mm holes were then cut into the   96 
agar using a sterile boring tube and the agar plugs removed. The wells were filled with 100 
uL of the test compounds in duplicate (chitosan, dextran, chitosan gel) at concentrations of 
5% as well as a control well filled with 100 uL of sterile 0.9% saline. All plates were then 
incubated for 24 hours at 35
0C aerobically, anaerobically or microaerophilically depending 
on the optimal growth conditions of the test organism. At the end of the incubation any 
zone of inhibition was measured and recorded. 
 
Microbial growth activity 
 
The ability of the test compounds (chitosan, dextran and CD gel) to support bacterial 
growth, hold a bacteriostatic state or show antibactericidal activity was assessed by 
inoculating 1 ml of 5% concentrations of the test compounds with 1 uL of a 0.5 
McFarlands standard suspension of the test organism (approximately 1.5 x 10
5 organisms 
per mL). These tests were performed in triplicate. 
Non-nutrient controls (sterile 0.9% saline) and growth controls (CFS broth, Oxoid 
Australia, Thebarton, South Australia) were also inoculated with the same bacterial 
suspension and all tubes were incubated for 24 hours at 35ºC aerobically or 
microaerophilically depending on the optimal growth conditions for the test organism. 
After incubation, 1 uL test compound, saline or CSF broth suspension was removed from 
each tube and lawn plated onto Blood or Chocolate agar (Oxoid Australia, Thebarton, 
South Australia) and then incubated for 24 hours at 35ºC under aerobic or microaerophilic 
conditions depending on the test organism. Following incubation, digital photographs of 
the agar plates containing colony forming units (CFU) were taken and later manually 
counted with digital marking using image editing software (Photoshop, Adobe). These 
were then compared with the non-nutrient sterile saline control tube.   97 
 
In-vitro anti-biofilm properties.  
 
To determine the action of CD gel and its constituents against in-vitro biofilms of various 
bacterial reference strains and clinical isolates appropriate for CRS, a 96-well micro-titre 
crystal-violet staining method was used. Our modified procedure was based on the method 
described by O’Toole and Kolter[122]. The organisms were prepared as described above 
for the macro-dilution method, the final desired inoculum concentration being 5 x 10
5 
CFU/mL. The organisms tested included the same ATCC strains used in the macro-
dilution method, as well as 4 clinical isolates of S. aureus from patients with CRS 
according to the criteria of the CRS Task Force 2003[123]. All organisms used were 
initially examined for biofilm forming capacity with the crystal violet method as well as 
confirmation via four chamber slide analysis using confocal scanning laser microscopy 
(CSLM) as previously described[55]. Only organisms that formed visible biofilm via 
CSLM monitoring were included in the analysis. 
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Prevention of biofilm growth 
 
One row of wells was filled with 100µL of CD gel (50µL of chitosan mixed with 50µL of 
dextran) and allowed to dry for 15 minutes.  The solidified gel was then evenly spread with 
a sterile micro-pipette tip to ensure complete coverage of the walls and base of the well. 
100µL of broth was added, along with 10µL of inoculum. The bacterial strains were 
evaluated in replicates of three at day 8 and the experiment repeated twice. Negative 
controls included CD gel coated wells with broth, without any addition of bacteria. 
Positive controls included broth and bacteria without any test agent. 
 
Inhibition of established biofilms 
 
Two rows of wells were filled with 200µL of broth and 10µL of inoculum and allowed to 
establish biofilm growth for a period of 8 days in 35ºC.  On alternate days, all wells 
underwent media change. 50µL of media was aspirated from each well using sterile micro-
pipette tips and replaced with 50-150µL of fresh media to prevent dehydration as this has 
previously been shown to allow maximal biofilm growth[55]. At day 8, once biofilms had 
established, the wells were treated separately with 100µL of dextran and 100µL of chitosan 
for 24 hours. A final row of wells contained untreated inoculated broth and was used as 
positive growth controls.  
 
Analysis of 96 well plates was conducted using a crystal violet assay and BioRad 
microplate reader (Hercules, CA) as previously described[55]. 
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Permanox chamber slide CLSM analysis 
 
The biofilm forming capacity of each reference strain was confirmed using Permanox 
chamber slides (Nunc, Roskilde, Denmark) and confocal laser microscopy (Leica 
Microsystems, Gretzwald) in a technique previously described[55].  
 
Statistics 
Statistical analysis was supported by an independent statistician provided by Statistics 
South Australia. Prevention of biofilm formation and inhibition of established biofilms 
were analysed using 2 way ANOVA with Bonferroni post test correction for multiple 






MIC and MBC of each test agent for each bacterial strain are displayed in graph 1 and 
graph 2. Apart from E. coli and P. aeruginosa, all bacterial strains tested were susceptible 
to dextran. In combination form, CD gel was both bactericidal and inhibitory to all strains 
except for E. coli. None of the bacteria tested were susceptible to chitosan at sub-clinical 
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Graph 2. 
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DISK DIFFUSION METHOD 
 
Growth inhibition as seen with disk diffusion method (graph 3) shows large zones of 
inhibition with dextran and CD gel for S.aureus, S.pneumoniae, S.bovis, P.aeruginosa and 
H.influenzae. In general, dextran had the greatest effect of growth inhibition with a slightly 
lesser inhibitory effect demonstrated by the CD gel. Chitosan only exhibited inhibition for 
S.bovis and E.faecalis.  
 
Graph 3.  
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MICROBIAL GROWTH ACTIVITY 
 
Colony forming unit counts for each bacterial strain are shown in graph 4. In optimal 
growth conditions, there was no bacterial growth with all microorganisms inoculated into 
dextran. Similarly CD gel had only negligible growth with E.coli and S.aureus recording 
an average of less than 1 CFU in this group. Chitosan did not support growth of 
S.pneumonia, S.bovis or H.influenzae and had CFU’s well below those of the positive 
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IN-VITRO ANTI-BIOFILM PROPERTIES 
 
Effect of CD gel on biofilm formation is shown in graph 5. There was significant 
reduction in formation of biofilm for all bacteria tested (p<0.01), apart from S.pneumoniae, 
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The effects of chitosan and dextran on formed mature biofilms can be seen in graphs 6 
and 7. There was no significant increase in biofilm formation with either compound. Both 
chitosan and dextran significantly reduced biofilm presence for S.aureus, E.coli, ATCC 
15435264 (p<0.01). In addition chitosan significantly reduced biofilm formation of ATCC 




Graph 6. Effect of Chitosan on mature biofilms compared to positive control 
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Graph 7. Effect of Dextran on mature biofilms compared to positive control   107 
DISCUSSION 
Overall the findings of this in vitro study suggest that CD gel has marked antimicrobial 
activity both against planktonic and biofilm forming bacteria. It was inhibitory and 
bactericidal at subclinical concentrations (25mg/ml) for all bacteria tested apart from E.coli 
(50mg/ml) and when compared to a nutrient free environment (saline) as well as a positive 
growth control (broth) bacteria were essentially unable to grow in its presence. This 
supports randomised clinical trial data that found that sinonasal cavities sprayed with the 
mucosal adhesive CD gel had reduced appearance of infection compared to control[124]. 
 
Chitosan alone was the least potent of tested substances. It was however bactericidal to all 
bacteria tested at concentrations of 50mg/ml and compared to broth was significantly less 
supportive of bacterial growth. Chitosan did not increase biofilm formation and indeed 
reduced biofilm mass for a number of the bacteria tested. 
Chitosan is thought to disrupt cell membranes as microbes settle on its surface[125] 
This compares well to a similar study which used reduction assay and CFU determinates to 
investigate the damaging effect of chitosan on Cryptococcus neoformans biofilms[126]. 
 
Dextran was the most potent agent tested against planktonic bacteria with very low 
bactericidal concentrations required for most bacteria (apart from P. aeruginosa and 
E.coli). In addition it had wide zones of inhibition for most bacteria tested and did not 
support growth of any bacteria as seen in the CFU count (fig 4). Its effect on biofilms was 
variable with reduction in biofilm mass seen with similar bacteria to chitosan as well as 
with H.influenzae. 
Dextran has been successfully used as a hydrogel coating for antifungal preparations and 
has been shown to penetrate the interior of biofilm cell clusters[127].    108 
 
A limitation of this study occurred in the testing of the in-vitro anti-biofilm effects of CD 
gel, and its components, chitosan and dextran. Different study methodologies were applied 
to investigate the effect on biofilm formation with contact-exposure to the test agents. 
Although an overall trend towards reduction of biofilm growth could be observed with 
treatment by all test compounds, the methodology could not be replicated in dextran and 
chitosan, as it was for CD gel. 
The components of CD gel, dextran and chitosan, prior to being combined, do not display 
the muco-adhesive properties afforded by CD gel, which allowed it to be smeared and 
rendered on the walls of the micro-wells of the 96-well plate. A reasonably consistent 
surface area for contact exposure to inoculated broth can be obtained in this way, and can 
also reduce the chance of removal of gel in the alternate daily media exchange procedure. 
Dextran and chitosan, are in aqueous states before they form a gel when combined, so it 
was not possible to achieve consistent contact surface area, because the addition of 
inoculated broth would then cause mixing. 
Therefore investigation of the constituent parts, chitosan and dextran, continued 
independent of CD gel, using the same protocol described in a preceding in vitro anti-
biofilm study [41]. 
The selection of bacterial strains in the in-vitro biofilm portion of the study was also 
considered a limitation. Only those bacterial strains that demonstrated biofilm-forming 
capacity on permanox chamber slide CLSM analysis, and a selection of clinically relevant 
strains isolated from CRS patients, were tested against the agents. A representative 
spectrum of clinically relevant bacteria, not identical to the group examined in the 
microbial susceptibility and MIC/MBC studies, was the result of this selection procedure.   109 
CD gel has previously been shown to have unique abilities in being both a potent 
hemostatic agent as well as assisting in sinonasal wound healing [51, 52, 124, 128]. The 
presence of antimicrobial activity in addition to haemostatic and wound healing properties 




Using standard measures of antimicrobial and antibiofilm activity we have investigated CD 
gel and its individual components - chitosan and dextran. Our results suggest CD gel has 
potent antibacterial and antibiofilm activity against a number of pathogenic organisms 
suspected of being involved in acute and chronic rhinosinusitis and therefore holds 
promise in its use as a nasal dressing. 
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The studies in this thesis were designed to assess the efficacy of potential anti-biofilm 
treatments. The trials provided opportunities to re-visit our evolving knowledge on the 
topic of bacterial biofilms and chronic rhinosinusitis, and to apply effective methods of 
biofilm detection and quantification. The well-established role of biofilms in the 
pathogenesis of CRS[9, 10, 12, 45] and their staggering resistance to conventional 
antimicrobials has compelled researchers to explore novel approaches to therapy[54, 59].  
 
In the first study we used a standardized in vivo sheep frontal sinus biofilm model [17] to 
examine the impact of various proposed anti-biofilm treatments on S. aureus biofilms. In 
the examination of the mucosal specimens, CSLM confirmed the presence of biofilms 
stained with Baclight fluorescent nucleic acid probes (Invitrogen, Molecular Probes), while 
S. aureus PNA FISH probes (AdanDx, MA) were used to quantify the extent of biofilm 
involvement. 
In the second study, in vitro biofilms of common CRS bacteria were used as a tool to 
evaluate the anti-biofilm properties of CD gel, a novel chitosan-based mucoadhesive 
dressing. The MIC’s and MBC’s of Chitosan, Dextran and the combined CD gel were also 
documented for various CRS pathogens, in their planktonic and biofilm modes of growth. 
 
   112 
A sheep frontal sinus model of CRS was developed by our department in a previous study 
of biofilms[17] and was considered a reliable in vivo model for the investigation of anti-
biofilm treatments. The ESS procedure in this sheep model used standard human 
endoscopic equipment to experimentally occlude the frontal sinus ostia, to allow for sinus 
inoculation with a standardized dilution of S. aureus. The previous study demonstrated 
consistent evidence of biofilm morphology in 100% of inoculated occluded sinuses on 
CSLM imaging[17]. In this study, an incubation period of 8 days was chosen as it 
represented the time of peak growth for S. aureus biofilms, according to in vitro data[55]. 
 
Although it is accepted that biofilms can be poly-microbial[12, 22, 45], S. aureus is one of 
the most commonly isolated micro-organisms from CRS patients and may play a role in 
the pathogenesis of the condition[105]. It is for this reason and its well-documented 
biofilm-forming capacity[80] that S. aureus (reference strain ATCC25923) was chosen as 
the target microbe for this intervention study. 
A number of potential anti-biofilm therapies were evaluated by in vivo and in vitro 
methods. Mupirocin (ENT Technologies, VIC) flushes; chemical surfactant (Citric Acid 
Zwitterionic Surfactant, Medtronic, FL) with hydro-pressure (Hydro-debrider, HD, 
Medtronic, FL); gallium nitrate (Sigma Aldrich, NSW); saline flushes, and 
chitosan/dextran (CD) gel. These act via various pathways to disrupt the potential barriers 
of resistance in biofilms.   113 
In the in vivo sheep study all sinuses receiving treatment showed a statistically significant 
reduction in biofilm surface area coverage compared to no treatment. 
The most impressive results were obtained from mupirocin flushes. A significant reduction 
in biofilm coverage (7.51%) was observed 24 hours after a single dose of mupirocin, 
trending towards further reduction (5.87%) by the 8
th day of follow-up. 
However, twice-daily mupirocin flushes over a period of 5 days reduced biofilms to 
negligible levels (0.84%) 8 days after the initial dose.  
Sinuses that received an intra-operative stat dose of gallium nitrate also showed an initial 
reduction in biofilm surface area coverage to 16.2%, with sustained reduction effect by day 
8 post-treatment (10.0% biofilm surface area coverage).  
Although initially effective in reducing biofilms 24 hours after its administration, 
CAZS/HD failed to show persistent effects. Biofilms in this group re-generated to involve 
21.95% of the mucosal surface area, approaching pre-treatment levels after 8 days. A 
plausible explanation for the re-accumulation of biofilms in this group may be that 
treatment by CAZS under hydrodynamic force is detrimental to the mucociliary function 
of the sinus mucosa. This was evident in the histological examination of the sinuses of 
New Zealand white rabbits exposed to CAZS solution, showing marked deciliation 
phenomenon, which required 6 days to normalize[129]. This, together with a residual 
biofilm load potentially too large for the innate immune system to clear, may result in 
regeneration of surviving biofilms. The response to regular treatment of the sheep sinuses 
with CAZS/HD was not assessed in our study. A possible correlation between biofilm 
reduction and duration of treatment was postulated with the repeated intensive use of 
mupirocin lavage. The same association could not be made for CAZS/HD treatment in this 
study. To achieve access, the hydrodebrider (HD) system used in the delivery of CAZS 
solution requires direct endoscopic visualization of the frontal sinus ostium. If regular   114 
CAZS/HD regimes were to be tested, the repeated induction of anaesthesia and technical 
difficulty of repeated surgery would preclude it from being performed comfortably in the 
sheep. 
 
There were obvious limitations to using the sheep model in the investigation of biofilms in 
CRS. Previously, sheep have been used extensively by our research department to study 
the histological effects of mucosal inflammation[50, 53]. Although the sheep have similar 
anatomical configuration of their sinuses as well as a similar ciliated mucosa, possible 
differences in the immunological response to bacteria has not been fully investigated. In 
this study, it was also assumed that the state of induced acute sinus infection and 
inflammation in sheep occurs as the pathological process of CRS in humans. The acute 
mucosal infection induced within the obstructed sheep frontal sinus, after an incubation 
period of 8 days, may not reflect the chronic inflammatory changes in muco-periosteum 
that exist in chronically infected human sinuses. Nonetheless, the sheep model allowed the 
study to be randomized and prospective in design, which in human subjects would be 
difficult to justify ethically.  
 
The mucosal samples, collected for immuno-histological and FISH analysis, were 
randomly selected from the frontal sinuses because of size limitations and mechanical and 
logistical restrictions imposed by the hybridization process and sophisticated CSLM 
equipment. The 1cm x 1cm mucosal samples were small enough for stable fixation and 
hybridization assays on glass mounts (SnowCoat, Surgipath) and coverslips, as well as 
mounting onto the automated Leica SP5 Spectral CSLM stage. The chosen area of mucosal 
tissue was considered technically ideal for the subsequent recording and analysis of 100 
random fields of view at 20x magnification. The mapping tool on the LAS-AF software   115 
(Leica Microsystems) was able to perform this procedure and record the high-resolution 
images within a reasonable timeframe of 20 minutes per sample. On average, the total time 
involved to harvest and hybridize the fresh mucosal samples by FISH assay, ready for 
fluorescent microscopy, was 120 minutes. Because the specimens tested were randomly 
selected from the sinus, it was felt that they should give a fair representation of the overall 
infective process of the entire sinus. The sample sizes in each of the treatment groups were 
divided not only between treatments but also between time of harvesting the specimens. Of 
the possible 54 sinuses randomized to a treatment regime, 52 received the complete 
treatment course. With the available number of sheep granted for use in this project, the 
authors considered it important to evaluate the effects of treatment not only 24 hours after 
the first dose but also 8 days later, in order to assess biofilm re-growth. The duplication of 
each treatment group for follow-up evaluation halved the sample sizes, but provided 
valuable data that was highly relevant to the paradigm of biofilm-mediated infection. 
Furthermore, the smaller sample sizes allowed more treatment arms to be investigated in a 
standardized method. Despite this, all groups showed reductions in biofilm surface area 
coverage that were statistically significant compared to no treatment, with the most 
remarkable reduction in the group treated with twice-daily flushes of mupirocin for 5 days. 
 
An assumption was made that the percentage of biofilm surface area coverage of mucosa 
equated to the degree of sinus disease. Surface area coverage included not only the 
intensely fluorescent staphylococci on CLSM, but also their self-produced surrounding 
exopolymeric matrix. Recording clinical data from the sheep and endoscopically assessing 
their sinuses would have added more information to our understanding of the syndrome of 
CRS, and would be considered in future extension of this work. To avoid the stresses of   116 
anesthetic induction involved in this semi-invasive clinical examination, post-mortem 
digital photographic evaluations of sheep’s harvested mucosa were carried out instead.  
   
The recent development of a novel absorbable haemostatic chitosan gel (CD gel) prompted 
research into its antibacterial properties against known biofilm-forming bacterial strains. 
Its mucosal healing properties demonstrated in in vivo sheep studies and its ability to 
prevent post-operative infection in other animal studies [52, 121] makes CD gel stand out 
as a potentially effective post-ESS nasal dressing. 
As part of the second study, well-established methods of in vitro biofilm growth[55] were 
revisited with the aim of demonstrating the susceptibilities of common CRS pathogens to 
this novel CD gel. Methods utilized in the first study, such as the detection of fluorescently 
labeled live biofilm bacteria and characteristic biofilm morphology, were used as 
evaluation tools in the second study. 
Biofilm-forming CRS bacteria and their planktonic counterparts were exposed to clinical 
concentrations of chitosan, dextran and CD gel. Subsequently an initial anti-microbial 
profile for CD gel and its components was established. 
According to the MIC and MBC data, CD gel was bacteriocidal and inhibitory at 
subclinical concentrations for all bacterial strains except for E. coli. This reflected similar 
findings in previous antibacterial research on low molecular weight chitosans [130]. 
However, dextran demonstrated remarkable growth inhibition across a large spectrum of 
bacterial test strains in the macro-dilution, disk-diffusion methods and in optimal growth 
conditions.  
Chitosan demonstrated poor anti-bacterial action, with none of the bacterial strains being 
susceptible at subclinical concentrations. However when combined with dextran to form 
CD gel, the synergy of positively charged polysaccharides and high-molecular weight   117 
carbohydrate produced significant bacteriocidal action, producing large zones of inhibition 
for S. aureus, S. pneumoniae, S. bovis, P. aeruginosa and H. influenzae. Importantly, 
chitosan alone did not support the growth of these potential CRS pathogens compared to 
positive growth controls. 
 
To test the potency of CD gel and its constituents against biofilm-forming strains of 
bacteria, a model of in vitro biofilm growth was followed based on a previously described 
method[55]. The pathogens were first checked for biofilm-forming capacity by inoculating 
broth-containing Permanox (Nunc, Roskilde, Denmark) plastic chamber slides over an 
optimal growth period, then washed and stained with the Live/Dead cell viability 
(Invitrogen) kit using standard protocols. The chambers were assessed for biofilm presence 
under CLSM, and only those organisms that formed visible biofilms were included in 
analysis using the micro-titre plate crystal-violet assay described by O’Toole and Kolter 
[2]. 
From the reduced optical density of the stained biofilms, it was demonstrated that CD gel 
had significant anti-biofilm action against CRS bacteria. The susceptible groups of bacteria 
included four clinical isolates of S. aureus. Furthermore, CD gel did not support the growth 
of in vitro biofilms compared to no treatment.  
Against mature biofilms, chitosan and dextran demonstrated variable anti-biofilm activity 
across the tested bacteria. The two components of CD gel significantly reduced biofilms 
formed by S. aureus, H. influenzae and one of the clinical isolates, and did not support 
biofilm growth in any of the remaining tested strains.     
 
A reduction in bacterial growth in the presence of dextran at supra-MIC levels suggests 
that a high-carbohydrate environment is not conducive to the growth and development of   118 
biofilms. The MIC and MBC of CD gel was well below safe and tolerable concentrations 
used in recent human clinical trials [131, 132]. More importantly, the data demonstrated 
that the use of CD gel and its components (dextran and chitosan) did not support 
planktonic or biofilm modes of bacterial growth. Coupled with its mucosal healing 
properties, CD gel’s added anti-bacterial and anti-biofilm action against organisms 
commonly implicated in CRS posits it as an ideal post-ESS dressing. 
 
One of the limitations of this study was in the application of chitosan and dextran to the 
96-well microtitre plate, because these separate components do not possess optimal 
surface-adhesive properties. In the clinical setting, chitosan and dextran were not designed 
as separate therapeutic applications, being inherently non-mucoadhesive in these states. 
Therefore, the components could not be smeared onto the walls of the micro-titre wells, as 
CD gel was, to produce consistent coverage of the plastic walls upon which the biofilms 
were to attach. Hence, for chitosan and dextran, an alternative but previously established 
assay technique[55] was used to determine their anti-biofilm efficacy against matured 
biofilms. This involved using the same crystal violet staining and optical density analysis 
method. Thus, a comparison of CD gel to its constituents, chitosan and dextran, could not 
be made with regard to its in vitro anti-biofilm actions. However, it was shown that all 
treatments, irrespective of their adhesive properties, did not increase biofilm density 
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CONCLUSION 
 
Chronic rhinosinusitis is a highly prevalent and debilitating disease that places significant 
socio-economic burdens on the community. Recent evidence has demonstrated the 
presence of bacterial biofilms on the mucosa of affected patients[43, 45, 73], suggesting its 
role in the pathogenesis of the condition. Biofilms are also implicated in other chronic 
diseases such as otitis media, chronic tonsillitis and cholesteatoma. The persistence of S. 
aureus and P. aeruginosa biofilms has been associated with poorer prognosis following 
endoscopic sinus surgery. CLSM has been used as a tool to confirm biofilm presence in 
refractory CRS and in those patients who require repeated surgery[43]. 
Using nucleic acid probes (Invitrogen Molecular Probes) and species-specific PNA FISH 
techniques to detect biofilms on fresh mucosal samples, we have explored the anti-biofilm 
characteristics of various topical agents in a validated sheep model of CRS. 
Topical anti-bacterial agents offer high mucosal killing concentrations and can be safely 
administered with lower serum concentration and hence lower systemic side effects. 
In the sheep biofilm model of CRS, mupirocin was markedly potent as anti-biofilm agent, 
reducing mucosal biofilm coverage within 24 hours after a single dose, trending towards 
further reduction after 8 days of follow-up. The most impressive results were obtained with 
twice daily applications of mupirocin over a treatment period of 5 days. Biofilms in this 
treatment group were effectively eradicated to negligible levels.  
The in vitro bacterial susceptibility data for Chitosan Dextran gel against a spectrum of 
biofilm-forming pathogens, including clinical isolates, were impressive for this novel 
chitin derivative. Together with its wound healing and haemostatic properties, CD gel   121 
promises to be an ideal post-ESS packing material that would prevent post-operative 
infection. 
A number of in vitro and in vivo experiments were conducted in this thesis to explore the 
efficacy of novel and exciting potential anti-biofilm therapies. Much anticipated future 
clinical trials of these agents, which have unique mechanisms of action, are currently 
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